The Evidence Behind mAbs

Comprehensive review of monoclonal antibody applications across multiple infectious diseases including respiratory viruses, HIV, rabies, and bacterial pathogens. Demonstrates the versatility of mAb platforms for both prophylaxis and treatment across diverse pathogen classes.

Groundbreaking trial of anti-malaria mAb CIS43LS showing a single low-dose subcutaneous injection provided season-long protection against Plasmodium falciparum infection in adults in Mali. Extends mAb prevention paradigm beyond respiratory viruses into parasitic disease—a historically intractable space.

Follow-up study demonstrating sustained efficacy of subcutaneous mAb administration for malaria prevention. Confirms that mAbs can substitute for vaccines in settings where vaccine development has stalled, with significant implications for global health.

Phase 3 trial demonstrating significant reduction in C. difficile infection recurrence with monoclonal antibody therapy. Represents successful application of mAbs in preventing recurrent bacterial infections, particularly important in healthcare settings.

Analysis of monoclonal antibodies as therapeutic alternatives for multidrug-resistant bacterial infections. Reviews the potential for mAbs to address the growing challenge of antimicrobial resistance in the post-pandemic healthcare landscape.